Meet Gert Ossenkoppele, our Volunteer of the Month

Can you tell us what you do for EHA and when you started? How did you became a volunteer? Who helped/encouraged you to become one?
I am lucky to be one of the first members of the EHA (member number 34).…

Publication of EHA Annual General Meeting 2023 minutes

EHA impact video



 

The 2023 EHA Annual General Meeting (AGM) took place in Frankfurt, Germany on June 9, 2023.

Computational Biology Training in Hematology Hall of Fame

Clinical Research Training in Hematology Hall of Fame

Translational Research Training in Hematology Hall of Fame

Publication of EHA Annual General Meeting 2024 minutes

The 2024 EHA Annual General Meeting (AGM) took place in the vibrant city of Madrid, Spain, on June 14, 2024. Scheduled on Friday during the EHA Annual Congress, the meeting was once more in a hybrid format.

Congress Sponsor Program

Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.

Addition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)

CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.

Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients.

 

The high cost of tyrosine kinase inhibitors developed for chronic myeloid leukemia is a major concern for the health care payers, especially in countries with restricted resources.